JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M512970200 on February 7, 2006

J. Biol. Chem., Vol. 281, Issue 14, 9490-9497, April 7, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/14/9490    most recent
M512970200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fukunaga, K.
Right arrow Articles by Levy, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fukunaga, K.
Right arrow Articles by Levy, B. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification and Functional Characterization of a Presqualene Diphosphate Phosphatase*

Koichi Fukunaga{ddagger}, Makoto Arita§1, Minoru Takahashi§, Andrew J. Morris, Michael Pfeffer{ddagger}, and Bruce D. Levy{ddagger}§2

From the {ddagger}Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, and the §Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115 and the Department of Cell and Developmental Biology, University of North Carolina, Chapel Hill, North Carolina 27599

Presqualene diphosphate (PSDP) is a bioactive lipid that rapidly remodels to presqualene monophosphate (PSMP) upon cell activation (Levy, B. D., Petasis, N. A., and Serhan, C. N. (1997) Nature 389, 985–990). Here, we have identified and characterized a phosphatase that converts PSDP to PSMP. Unlike the related polyisoprenyl phosphate farnesyl diphosphate (FDP), PSDP was not a substrate for type 2 lipid phosphate phosphohydrolases. PSDP phosphatase activity was identified in activated human neutrophil (PMN) extracts and partially purified in the presence of Nonidet P-40 with gel filtration and anion exchange chromatography. Peptide sequencing of a candidate phosphatase was consistent with phosphatidic acid phosphatase domain containing 2 (PPAPDC2), an uncharacterized protein that contains a lipid phosphate phosphohydrolase consensus motif. Recombinant PPAPDC2 displayed diphosphate phosphatase activity with a substrate preference for PSDP > FDP > phosphatidic acid. PPAPDC2 activity was independent of Mg2+ and optimal at pH 7.0 to 8.0. Incubation of [14C]FDP with recombinant human squalene synthase led to [14C]PSDP and [14C]squalene formation, and in the presence of PPAPDC2, [14C]PSMP was generated from [14C]PSDP. PPAPDC2 mRNA was detected in human PMN, and is widely expressed in human tissues. Together, these findings indicate that PPAPDC2 in human PMN is the first lipid phosphate phosphohydrolase identified for PSDP. Regulation of this activity of the enzyme may have important roles for PMN activation in innate immunity.


Received for publication, December 5, 2005 , and in revised form, February 6, 2006.

* This work was supported in part by National Institutes of Health Grants HL68669 and P50-DE016191 (to B. D. L.) and post-doctoral fellowships from Pfizer and the Uehara Memorial Research Foundation (to K. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the Japanese Society for the Promotion of Science for Research Abroad.

2 To whom correspondence should be addressed. Tel.: 617-732-4353; Fax: 617-732-7421; E-mail: blevy{at}partners.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
N. M. Jackson and T. A. Kocarek
Suppression of CYP2B Induction by Alendronate-Mediated Farnesyl Diphosphate Synthase Inhibition in Primary Cultured Rat Hepatocytes
Drug Metab. Dispos., October 1, 2008; 36(10): 2030 - 2036.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
O. Haworth and B. D. Levy
Endogenous lipid mediators in the resolution of airway inflammation
Eur. Respir. J., November 1, 2007; 30(5): 980 - 992.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C. Bonnans and B. D. Levy
Lipid Mediators as Agonists for the Resolution of Acute Lung Inflammation and Injury
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 201 - 205.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.